Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;97(6):555-583.
doi: 10.1159/000543033. Epub 2024 Dec 14.

ISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents

Amy S Shah  1 , Margarita Barrientos-Pérez  2 , Nancy Chang  3 , Jun-Fen Fu  4 , Tamara S Hannon  5 , Megan Kelsey  6 , Alexia S Peña  7 , Orit Pinhas-Hamiel  8 , Tatsuhiko Urakami  9 , Brandy Wicklow  10 , Jencia Wong  11 , Farid H Mahmud  12
Affiliations
Review

ISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents

Amy S Shah et al. Horm Res Paediatr. 2024.

Abstract

Youth-onset type 2 diabetes (T2D) results from genetic, environmental, and metabolic causes that differ among individuals and populations. This chapter builds on the 2022 ISPAD guidelines and summarizes recent advances in the management of T2D in children and adolescents. Updates include diagnostic algorithm for youth with new onset T2D, algorithms and tables for treatment, management, and assessment of comorbidities and complications and recommendations on recently approved pharmacologic therapies for the treatment of youth-onset T2D and management strategies. Youth-onset type 2 diabetes (T2D) results from genetic, environmental, and metabolic causes that differ among individuals and populations. This chapter builds on the 2022 ISPAD guidelines and summarizes recent advances in the management of T2D in children and adolescents. Updates include diagnostic algorithm for youth with new onset T2D, algorithms and tables for treatment, management, and assessment of comorbidities and complications and recommendations on recently approved pharmacologic therapies for the treatment of youth-onset T2D and management strategies.

Keywords: Adolescents; Children; Complications; Management; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest to report.

Figures

Fig. 1.
Fig. 1.
Diagnosis of new onset diabetes in youth.
Fig. 2.
Fig. 2.
Evaluation and management of new onset T2D.
Fig. 3.
Fig. 3.
Blood pressure evaluation and management in youth with T2D.
Fig. 4.
Fig. 4.
Lipid evaluation and management in youth with T2D.
See this image and copyright information in PMC

References

    1. Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci. 2015;1353:113–37. - PubMed
    1. Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, et al. . Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes. 2011;60(5):1552–60. - PMC - PubMed
    1. TODAY Study Group . Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care. 2013;36(6):1749–57. - PMC - PubMed
    1. RISE Consortium; RISE Consortium Investigators . Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on β-cell function: comparison of responses in youth and adults. Diabetes. 2019;68(8):1670–80. - PMC - PubMed
    1. Ehrmann DA, Temple KA, Rue A, Barengolts E, Mokhlesi B, Van Cauter E, et al. . Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. Observations using the hyperglycemic clamp. Diabetes Care. 2018;41(8):1696–706. - PMC - PubMed